James M. Frates - 18 Aug 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
20 Aug 2026, 21:00:09 UTC
Prior SEC filing
09 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

James M. Frates filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 20 Aug 2026.

Key facts

  • This page summarizes James M. Frates's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 20 Aug 2026, 21:00.

Change

  • Previous filing in this sequence was filed on 09 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235598 Primary reporting owner

FRATES JAMES M

Relationship
Chief Financial Officer
Address
C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Signature date
20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Award

Transaction value
Shares
+22,807
Change %
+10%
Price
$0.000000*
Shares after
244,435
Date
18 Aug 2026
Ownership
Direct
Footnotes
F1
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
100,000
Date
18 Aug 2026
Ownership
By Trust
Footnotes
F2
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
15,459
Date
18 Aug 2026
Ownership
By Trust
Footnotes
F3
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
11,072
Date
18 Aug 2026
Ownership
By Trust
Footnotes
F4
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
40,000
Date
18 Aug 2026
Ownership
By Trust
Footnotes
F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

Footnote F2

Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F3

Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F4

Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F5

Reflects 40,000 shares previously reported as directly beneficially owned by the Reporting Person, which were transferred to the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1 on August 7, 2026 for no consideration. Such transfer constituted a change in form of beneficial ownership, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended.

Footnote F6

Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .